Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Clinical and ultrasound diagnosis of ADPKD~* GFR 40-15 ml/min/1.73 m2 (estimated by the 4 variable MDRD equation)~* Urinary protein excretion rate \< 0.5 g/ 24 hrs~* Written informed consent~Exclusion Criteria:~* Diabetes~* Urinary protein excretion rate \>0.5 g/ 24 hrs or abnormal urinalysis suggestive of concomitant, clinically significant glomerular disease~* Urinary tract lithiasis, infection or obstruction~* Cancer~* Psychiatric disorders and any condition that might prevent full comprehension of the purposes and risks of the study~* Pregnancy, lactation or child bearing potential and ineffective contraception (estrogen therapy in post menopausal women should not be stopped)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sirolimus (Type: EXPERIMENTAL): None
- conventional therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).